Higher Long COVID Risk Documented in Rheumatic Disease Patients
Adults with autoimmune rheumatic diseases face a 56 percent higher risk of developing documented Long COVID after a SARS-CoV-2 infection than patients without those conditions, according to a large retrospective cohort analysis published in Arthritis & Rheumatology. Researchers utilizing data from the National Clinical Cohort Collaborative evaluated 187,106 adult patients to establish the figures, tracking infections documented between September 2021 and December 2023 with follow-up extending through December 2024.
Cohort Data Reveals 2.8 Percent Diagnosis Rate
In the matched cohort analysis published in Arthritis & Rheumatology, documented Long COVID occurred in 2.8% of patients with autoimmune rheumatic diseases compared with 1.5% of matched controls without those conditions. The study team used 1:1 nearest-neighbour propensity score matching on age, along with exact matching on sex, race/ethnicity, data-contributing organisation, and the dominant SARS-CoV-2 variant period. Long COVID was identified using the International Classification of Diseases, 10th Revision, Clinical Modification code U09.9, or via a designated Long COVID clinic visit occurring between 28 and 365 days following the initial infection.
Biological Context and Immune System Factors
Separate Yale-led research provides biological context for post-infection complications by demonstrating that antibodies from certain patients with Long COVID attacked brain and nerve tissues. When investigators transferred these patient antibodies into healthy mice, the animals developed increased pain sensitivity, fatigue, impaired balance, and small nerve fiber damage.
Clinical Evaluation of Post-Infection Symptoms
For rheumatologists counseling patients following a SARS-CoV-2 infection, experts recommend initiating follow-up by asking what has failed to return to normal since the initial illness. Clinicians should specifically inquire about persistent fatigue, brain fog, reduced stamina, and daily functional changes, comparing those answers directly against the patient’s pre-infection baseline. This timeline helps differentiate between an underlying rheumatic disease flare and post-acute sequelae of COVID-19.
Frequently Asked Questions About Rheumatic Disease and Long COVID
What specific autoimmune rheumatic diseases were analyzed in the cohort study?
The study evaluated adults with autoimmune rheumatic diseases, including patients receiving immunomodulatory therapy, and identified Sjögren’s syndrome as being specifically associated with a higher risk of developing Long COVID.
What database provided the records for the 187,106 patients in the study?
Researchers assembled the retrospective cohort using data from the National Clinical Cohort Collaborative, tracking adults with a first documented SARS-CoV-2 infection between September 2021 and December 2023.
How did researchers identify cases of Long COVID in the patient population?
Cases were defined using the International Classification of Diseases, 10th Revision, Clinical Modification code U09.9, or through a documented Long COVID clinic visit occurring 28 to 365 days after the initial infection.
Related reading